S. Douglas

发表

Effects of p38 MAPK Inhibitor on Angiotensin II-Dependent Hypertension, Organ Damage, and Superoxide Anion Production

W. Bao, D. Behm, S. Nerurkar, 2007, Journal of cardiovascular pharmacology.

Endothelial modulation and changes in endothelin pressor activity during hypoxia in the rat isolated perfused superior mesenteric arterial bed

S. Douglas, C. Hiley, S. James, 1991, British journal of pharmacology.

Urotensin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

D. Webb, H. Krum, H. Vaudry, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

2-Aminomethyl piperidines as novel urotensin-II receptor antagonists.

L. Mcmillan, D. Behm, S. Douglas, 2008, Bioorganic & medicinal chemistry letters.

Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.

N. Aiyar, D. Behm, S. Douglas, 2008, Bioorganic & medicinal chemistry letters.

Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides.

H. Sarau, J. Foley, N. Aiyar, 2008, Bioorganic & medicinal chemistry letters.

N-alkyl-5H-pyrido[4,3-b]indol-1-amines and derivatives as novel urotensin-II receptor antagonists.

S. Douglas, Yonghui Wang, R. Rivero, 2008, Bioorganic & medicinal chemistry letters.

Aminomethylpiperazines as selective urotensin antagonists.

D. Behm, S. Douglas, Zining Wu, 2008, Bioorganic & medicinal chemistry letters.

Non-peptidic urotensin-II receptor modulators

S. Douglas, Jian Jin, 2006 .

Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists.

G. Warren, H. Sarau, J. Foley, 2005, Bioorganic & medicinal chemistry letters.

From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function.

D. Johns, S. Douglas, D. Dhanak, 2004, Trends in pharmacological sciences.

Identification and pharmacological characterization of native, functional human urotensin‐II receptors in rhabdomyosarcoma cell lines

N. Aiyar, Z. Ao, S. Douglas, 2004, British journal of pharmacology.

Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.

D. Behm, S. Douglas, S. Salvadori, 2004, European journal of pharmacology.

Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?

S. Douglas, 2003, Current opinion in pharmacology.

The neuromedin B receptor antagonist, BIM‐23127, is a potent antagonist at human and rat urotensin‐II receptors

H. Sarau, J. Foley, D. Behm, 2003, British journal of pharmacology.

Chapter 11. Urotensin-II receptor modulators

S. Douglas, D. Dhanak, M. Neeb, 2003 .

Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators

N. Aiyar, Z. Ao, D. Johns, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

The peptidic urotensin‐II receptor ligand GSK248451 possesses less intrinsic activity than the low‐efficacy partial agonists SB‐710411 and urantide in native mammalian tissues and recombinant cell systems

H. Sarau, R. Ames, J. Foley, 2006, British journal of pharmacology.

Trypanosoma cruzi infection (Chagas' disease) of mice causes activation of the mitogen-activated protein kinase cascade and expression of endothelin-1 in the myocardium.

G. Christ, S. Douglas, M. Lisanti, 2000, Journal of cardiovascular pharmacology.

Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist.

N. Aiyar, S. Douglas, R. Willette, 2001, The Journal of pharmacology and experimental therapeutics.

The role of endothelin in the pathogenesis of Chagas' disease.

S. Douglas, R. Pestell, B. Bouzahzah, 2001, International journal for parasitology.

Myocardial expression of endothelin-1 in murine Trypanosoma cruzi infection.

G. Christ, S. Douglas, S. Morris, 2000, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

The putative mechanistic basis for the modulatory role of endothelin-1 in the altered vascular tone induced by Trypanosoma cruzi.

G. Christ, S. Douglas, S. Morris, 1999, Endothelium : journal of endothelial cell research.

Urotensin II and renal function in the rat.

Z. Ao, D. Johns, S. Douglas, 2006, Kidney international.

Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta.

S. Douglas, E. Ohlstein, N. Bousette, 2004, Atherosclerosis.

Deletion of the UT receptor gene results in the selective loss of urotensin‐II contractile activity in aortae isolated from UT receptor knockout mice

David G. Behm, D. Behm, Z. Ao, 2003, British journal of pharmacology.

Effect of human urotensin-II infusion on hemodynamics and cardiac function.

Z. Ao, S. Douglas, R. Willette, 2003, Canadian journal of physiology and pharmacology.

Localization of Urotensin-II Immunoreactivity in Normal Human Kidneys and Renal Carcinoma

S. Douglas, E. Ohlstein, A. Giaid, 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Central effects of urotensin-II following ICV administration in rats

J. Hagan, S. Douglas, G. Riley, 2001, Psychopharmacology.

Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey

H. Sarau, R. Ames, N. Aiyar, 2000, British journal of pharmacology.

Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

S. Douglas, E. Ohlstein, 2000, Trends in cardiovascular medicine.

Cardioprotective effects of phosphoramidon on myocardial structure and function in murine Chagas' disease.

G. Christ, S. Douglas, M. Teixeira, 2002, International journal for parasitology.

Contractile responses to human urotensin‐II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat

S. Douglas, M. Maclean, E. Ohlstein, 2000, British journal of pharmacology.

Human urotensin‐II is an endothelium‐dependent vasodilator in rat small arteries

S. Douglas, C. Hiley, F. Bottrill, 2000, British journal of pharmacology.

Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein

J. D. Elliott, S. Douglas, E. Ohlstein, 1995, British journal of pharmacology.

Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy

David G. Behm, H. Krum, S. Douglas, 2010, Peptides.

Direct Inotropic Effects of Exogenous and Endogenous Urotensin-II: Divergent Actions in Failing and Nonfailing Human Myocardium

S. Douglas, K. Margulies, H. Kubo, 2009, Circulation. Heart failure.

Direct Inotropic Effects of Exogenous and Endogenous Urotensin-II: Divergent Actions in Failing and Non-Failing Human Myocardium

S. Douglas, K. Margulies, H. Kubo, 2008 .

Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury.

S. Douglas, T. Yue, G. Poste, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Urotensin II Receptor Knockout Mice on an ApoE Knockout Background Fed a High-Fat Diet Exhibit an Enhanced Hyperlipidemic and Atherosclerotic Phenotype

David G. Behm, A. Gramolini, R. S. Kiss, 2009, Circulation research.

Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells

N. Aiyar, S. Nerurkar, Z. Ao, 2006, Molecular and Cellular Biochemistry.

A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670.

J. D. Elliott, S. Douglas, G. Feuerstein, 1994, Circulation research.

Regional vasodilation to endothelin-1 is mediated by a non-ETA receptor subtype in the anaesthetized rat: effect of BQ-123 on systemic haemodynamic responses.

J. D. Elliott, S. Douglas, E. Ohlstein, 1992, European journal of pharmacology.

The Role of Translational Medicine and Predictive Biomarkers in the Development of Novel, Innovative Treatments for the Management of Chronic Heart Failure: A Pharmaceutical Industry Perspective

S. Douglas, G. Feuerstein, 2010 .

In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4–11) (UFP‐803)

S. Douglas, S. Salvadori, D. Lambert, 2006, British journal of pharmacology.

Nonpeptidic urotensin‐II receptor antagonists I: in vitro pharmacological characterization of SB‐706375

David G. Behm, H. Sarau, J. Foley, 2005, British journal of pharmacology.

Cloning and pharmacological characterization of the cat urotensin-II receptor (UT).

H. Sarau, J. Foley, N. Aiyar, 2005, Biochemical pharmacology.

Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors.

N. Aiyar, D. Behm, S. Douglas, 2004, European journal of pharmacology.

Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease

S. Douglas, E. Ohlstein, D. Dhanak, 2006, Peptides.

Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues

N. Aiyar, D. Behm, S. Douglas, 2008, British journal of pharmacology.

Trypanosoma cruzi induces endothelin release from endothelial cells.

G. Christ, S. Douglas, S. Morris, 1995, The Journal of infectious diseases.

Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat.

S. Douglas, G. Feuerstein, E. Ohlstein, 1996, Circulation research.

Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.

D. Holt, D. Behm, S. Douglas, 2013, Bioorganic & medicinal chemistry letters.

BQ‐123, a selective endothelin subtype A‐receptor antagonist, lowers blood pressure in different rat models of hypertension

S. Douglas, E. Ohlstein, M. Gellai, 1994, Journal of hypertension.

NADPH oxidase-dependent and -independent mechanisms of reported inhibitors of reactive oxygen generation

Z. Ao, D. Johns, S. Douglas, 2013, Journal of enzyme inhibition and medicinal chemistry.

Urotensin receptor in GtoPdb v.2021.3

D. Webb, H. Krum, H. Vaudry, 2021, IUPHAR/BPS Guide to Pharmacology CITE.

Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670.

J. D. Elliott, S. Douglas, R. Ruffolo, 1994, The Journal of pharmacology and experimental therapeutics.

Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease.

H. Krum, S. Douglas, R. Gilbert, 2004, Current opinion in investigational drugs.

Functional evidence that balloon angioplasty results in transient nitric oxide synthase induction.

S. Douglas, E. Ohlstein, L. Vickery-Clark, 1994, European journal of pharmacology.

Endothelin‐1 modulates vascular smooth muscle structure and vasomotion: Implications in cardiovascular pathology

S. Douglas, E. Ohlstein, Eliot H. Ohlstein, 1993 .

GSK1562590, a slowly dissociating urotensin‐II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo

N. Aiyar, D. Behm, S. Douglas, 2010, British journal of pharmacology.

Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet.

D. Behm, S. Douglas, E. Ohlstein, 2009, Atherosclerosis.

Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation.

S. Douglas, E. Ohlstein, D. Dhanak, 2006, Journal of molecular and cellular cardiology.

Clinical development of endothelin receptor antagonists.

S. Douglas, 1997, Trends in pharmacological sciences.

Antihypertensive effects of the endothelin receptor antagonist BQ-123 in conscious spontaneously hypertensive rats.

S. Douglas, E. Ohlstein, M. Gellai, 1993, Journal of cardiovascular pharmacology.

Endothelium‐dependent mesenteric vasorelaxant effects and systemic actions of endothelin (16–21) and other endothelin‐related peptides in the rat

S. Douglas, C. Hiley, 1991, British journal of pharmacology.

Endothelium‐dependent vascular activities of endothelin‐like peptides in the isolated superior mesenteric arterial bed of the rat

S. Douglas, C. Hiley, 1990, British journal of pharmacology.

Endothelin‐1 does not mediate hypoxic vasoconstriction in canine isolated blood vessels: effect of BQ‐123

S. Douglas, E. Ohlstein, L. Vickery-Clark, 1993, British journal of pharmacology.

Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle.

N. Aiyar, D. Behm, Z. Ao, 2005, European journal of pharmacology.

Human urotensin‐II is a potent spasmogen of primate airway smooth muscle

S. Douglas, D. Hay, M. Luttmann, 2000, British journal of pharmacology.

Molecular cloning and pharmacological characterization of bovine calcitonin receptor-like receptor from bovine aortic endothelial cells.

N. Aiyar, Z. Ao, S. Douglas, 2002, Biochemical pharmacology.

Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate.

N. Aiyar, R. Coatney, S. Douglas, 2000, Journal of cardiovascular pharmacology.

Meeting reportClinical development of endothelin receptor antagonists

S. Douglas, 1997 .

Temporal Expression of ECE‐1, ET‐1, ET‐3, ETA, and ETB Receptor mRNAs After Balloon Angioplasty in the Rat

S. Douglas, G. Feuerstein, E. Ohlstein, 1995, Journal of cardiovascular pharmacology.

Endothelin-1 promotes neointima formation after balloon angioplasty in the rat.

S. Douglas, E. Ohlstein, Stephen A. Douglas, 1993, Journal of cardiovascular pharmacology.

Direct Inotropic Effects of Exogenous and Endogenous Urotensin-IICLINICAL PERSPECTIVE

S. Douglas, K. Margulies, H. Kubo, 2009 .

Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor.

N. Aiyar, N. Elshourbagy, Z. Ao, 2007, Biochemical and biophysical research communications.

Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate.

N. Aiyar, R. Coatney, S. Douglas, 2000, Journal of cardiovascular pharmacology.

Differential modulation of endothelin ligand‐induced contraction in isolated tracheae from endothelin B (ETB) receptor knockout mice

Z. Ao, S. Douglas, P. Rigby, 2001, British journal of pharmacology.

SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist.

S. Douglas, E. Ohlstein, P. Nambi, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Responses to endothelin-1, human proendothelin (1–38) and porcine proendothelin (1–39) in the rat on intravenous administration and in the blood perfused mesentery

S. Douglas, C. Hiley, 1991, Neurochemistry International.

Pharmacologic characterization of the novel, orally available endothelin-A--selective antagonist SB 247083.

J. D. Elliott, J. Luengo, S. Douglas, 1998, Journal of cardiovascular pharmacology.

Vascular Smooth Muscle Function in Rats with Acute Renal Failure

M. S. Yates, S. Douglas, C. Bowmer, 1989, The Journal of pharmacy and pharmacology.

Phosphoramidon treatment improves the consequences of chagasic heart disease in mice.

G. Christ, S. Douglas, L. Weiss, 2002, Clinical science.

Pressor Effects of Endothelin‐1 and Some Analogs in the Perfused Superior Mesenteric Arterial Bed of the Rat

S. Douglas, C. Hiley, M. Randall, 1989, Journal of Cardiovascular Pharmacology.

Selective ETA receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the rat.

S. Douglas, E. Ohlstein, C. Louden, 1995, Cardiovascular research.

Erosive gastritis and gastrointestinal bleeding in a female runner. Prevention of the bleeding and healing of the gastritis with H2-receptor antagonists.

S. Douglas, B. Cooper, V. Chadwick, 1987, Gastroenterology.

Differential levels of “urotensin-II-like” activity determined by radio-receptor and radioimmuno-assays

David G. Behm, N. Aiyar, Z. Ao, 2004, Peptides.

erratum: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

H. Sarau, R. Ames, J. Foley, 1999, Nature.

Congestive heart failure and expression of myocardial urotensin II

S. Douglas, E. Ohlstein, A. Giaid, 2002, The Lancet.

The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects

S. Dowell, N. Aiyar, W. Bao, 2007, British journal of pharmacology.

In vivo pharmacological characterization of the non‐peptide endothelin receptor antagonist SB 209670

J. D. Elliott, S. Douglas, E. Ohlstein, 1995, British journal of pharmacology.

Quantitative analysis of orphan G protein-coupled receptor mRNAs by TaqMan Real-Time PCR: G2A and GPR4 lysophospholipid receptor expression in leukocytes and in a rat myocardial infarction-heart failure model.

P. Murdock, Z. Ao, D. Johns, 2005, Methods in molecular biology.

Vascular and Cardiac Effects of Endothelin

S. Douglas, E. Ohlstein, 2001 .

Pharmacologic Evidence for the Presence of Three Functional Endothelin Receptor Subtypes in Rabbit Saphenous Vein

J. D. Elliott, S. Douglas, E. Ohlstein, 1995, Journal of cardiovascular pharmacology.

Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

H. Sarau, R. Ames, J. Foley, 1999, Nature.

Vascular activities of endothelin‐1 and some alanyl substituted analogues in resistance beds of the rat

S. Douglas, C. Hiley, M. Randall, 1989, British journal of pharmacology.

Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670.

J. D. Elliott, S. Douglas, G. Feuerstein, 1995, Hypertension.

Expression of urotensin-II in human coronary atherosclerosis

S. Douglas, E. Ohlstein, Ghada S. Hassan, 2005, Peptides.

A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker.

S. Douglas, E. Ohlstein, Ghada S. Hassan, 2005, Journal of molecular and cellular cardiology.

Rosiglitazone Protects against Ischemia/Reperfusion-Induced Leukocyte Adhesion in the Zucker Diabetic Fatty Rat

Z. Ao, D. Johns, S. Douglas, 2005, Journal of Pharmacology and Experimental Therapeutics.

p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 1. p38 MAPK-Dependent Endothelial Dysfunction and Hypertension

D. Behm, S. Douglas, R. Willette, 2003, Journal of Pharmacology and Experimental Therapeutics.

Molecular and pharmacological characterization of genes encoding urotensin‐II peptides and their cognate G‐protein‐coupled receptors from the mouse and monkey

N. Aiyar, N. Elshourbagy, Z. Ao, 2002, British journal of pharmacology.

Techniques: Cardiovascular pharmacology and drug discovery in the 21st century.

D. Johns, S. Douglas, E. Ohlstein, 2004, Trends in pharmacological sciences.

Role of p38 MAP kinase in postcapillary venule leukocyte adhesion induced by ischemia/reperfusion injury.

Z. Ao, D. Johns, S. Douglas, 2005, Pharmacological research.

Urotensin-II: a novel systemic hypertensive factor in the cat

D. Behm, D. Johns, C. Doe, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist

David G. Behm, S. Douglas, E. Ohlstein, 2002, British journal of pharmacology.

Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries.

S. Douglas, M. Maclean, E. Ohlstein, 2001, American journal of physiology. Heart and circulatory physiology.

Signal transduction mechanisms mediating the vascular actions of endothelin.

S. Douglas, E. Ohlstein, 1997, Journal of vascular research.

Endothelin B receptor modulates inflammatory pain and cutaneous inflammation.

Z. Ao, S. Douglas, E. Ohlstein, 1999, Molecular pharmacology.

Epoxyeicosatrienoic Acids Function as Selective, Endogenous Antagonists of Native Thromboxane Receptors: Identification of a Novel Mechanism of Vasodilation

D. Behm, S. Douglas, Charlene W. Wu, 2009, Journal of Pharmacology and Experimental Therapeutics.

Novel receptor antagonists welcome a new era in endothelin biology.

S. Douglas, E. Ohlstein, T. Meek, 1994, Trends in pharmacological sciences.

P2X1 stimulation promotes thrombin receptor‐mediated platelet aggregation

S. Douglas, J. Erhardt, D. Johns, 2006, Journal of thrombosis and haemostasis : JTH.

Development of potent and selective small-molecule human Urotensin-II antagonists.

N. Aiyar, D. Behm, S. Douglas, 2008, Bioorganic & medicinal chemistry letters.

Endothelin Receptor Subtypes in the Pathogenesis of Angioplasty‐Induced Neointima Formation in the Rat: A Comparison of Selective ETA Receptor Antagonism and Dual ETA/ETB Receptor Antagonism Using BQ‐123 and SB 209670

J. D. Elliott, S. Douglas, E. Ohlstein, 1995, Journal of cardiovascular pharmacology.

Heme-oxygenase induction inhibits arteriolar thrombosis in vivo: effect of the non-substrate inducer cobalt protoporphyrin.

M. Jaye, Z. Ao, D. Johns, 2009, European journal of pharmacology.

Urotensin-II Immunoreactivity in Normolipidemic and Hyperlipidemic New Zealand White Rabbits Following Balloon Angioplasty and Stenting

S. Douglas, E. Ohlstein, F. Chouiali, 2007, International journal of biomedical science : IJBS.

Vascular activities ofendothelin- 1andsomealanyl substituted analogues inresistance bedsoftherat

S. Douglas, M. Randall, C. RobinHiley, 1989 .

Identification and characterization of binding sites for human urotensin-II in Sprague–Dawley rat renal medulla using quantitative receptor autoradiography

N. Aiyar, S. Douglas, J. Disa, 2006, Peptides.

Production and characterization of monoclonal antibodies against the vasoconstrictive peptide human urotensin-II.

N. Aiyar, Z. Ao, S. Douglas, 2003, Hybridoma and hybridomics.

Use of differential display to identify differentially expressed mRNAs induced by rat carotid artery balloon angioplasty.

S. Douglas, G. Feuerstein, E. Ohlstein, 1995, Laboratory investigation; a journal of technical methods and pathology.